BPC-157 Side Effects: FDA Reports and Human Study Findings

What serious reactions have actually been reported in people?

FDA searched its adverse-event database through December 4, 2025 and found three reports, all for injectable BPC-157 [1].

• Injection-site redness and swelling lasting nine days; that patient also used compounded thymosin [1].
• Shortness of breath that led to an emergency room visit; FDA's summary gives no further detail [1].
• Widespread darkening of the skin and gums, which came back when the person was re-exposed to a 'research' product containing BPC-157 plus TB-500 [1].

FDA said it cannot tell whether BPC-157 caused these events [1]. Three reports cannot show how often serious reactions occur.

What the human studies found

In the small human studies FDA reviewed, no serious adverse events were reported; the studies were short and small, with limited safety information [1]. In the healthy-volunteer enema studies (meeting abstracts), the most frequent events were headache and flatulence [1].

Three published studies assessed 30 people in total:

• A retrospective chart review of 17 patients treated at one Florida clinic for knee pain, 16 of whom were reached by phone; no adverse events were noted [3].
• A single-arm pilot in 12 women with interstitial cystitis who received 10 mg injected around the bladder wall during one procedure; no adverse events were reported [4].
• A two-person intravenous pilot using 10 mg on day one and 20 mg on day two, with no measurable change in the tested heart, liver, kidney, thyroid or glucose markers and no side effects reported; two participants cannot establish safety [5].

A separate ulcerative colitis enema trial in 53 people, compared with placebo, exists only as a meeting abstract. The abstract says the treatment was well tolerated, with no difference in adverse events versus placebo, but FDA said it has too little detail to judge effectiveness and no full paper exists [1].

A 2026 systematic review of orthopaedic and regenerative use found only the three published studies, all of poor methodological quality, with certainty of evidence rated very low; the reviewers concluded BPC-157 should not be used clinically outside ethically approved, regulated, high-quality trials [6].

What animal toxicity studies flagged

In 28-day intramuscular studies, BPC-157 shortened clotting time (aPTT) in rats and lengthened it in dogs, and raised liver enzyme (ALT), glucose and triglyceride levels [1]. Longer studies and cancer-risk studies were not available [1].

Does BPC-157 cause cancer?

FDA reported that cancer-risk studies of BPC-157 were not available [1]. FDA also said the peptide's molecular targets have not been identified, its mechanisms 'remain poorly understood', and dose-response relationships for its reported protective effects were not established [1]. Those reported effects, such as preventing colonic fistulas and gut or liver lesions, come from rat studies rather than human trials [1].

Immunogenicity and product quality: FDA's stated concerns

FDA's page on bulk substances that may raise safety concerns when compounded carries BPC-157 in its 'nominated but withdrawn' table and still states that compounded BPC-157 'may pose risk for immunogenicity for certain routes of administration' and may have problems with peptide-related impurities and characterization of the active ingredient [7]. The same page says FDA 'has identified no, or only limited, safety-related information for the proposed routes of administration' and therefore 'lacks sufficient information to know whether the drug would cause harm when administered to humans' [7].

Which routes have human safety data, and which do not

FDA found no human studies of BPC-157 given by mouth, by subcutaneous injection, by nasal spray or on the skin [1]. After rectal enemas in two early studies the peptide was mostly not detectable in blood, and FDA judged that it appears not to be absorbed systemically by that route [1].

Human reports include rectal enemas, injections into the knee or bladder wall, and a two-person intravenous pilot [1][3][4][5]. FDA noted that websites sell BPC-157 as capsules, injections, oral sprays and nasal sprays, some labeled 'for research purposes only and not for human or veterinary use'; those products are not FDA-approved drugs [1].

Regulatory status and safety reporting

BPC-157 is not an FDA-approved drug. No approved drug contains it, there is no US Pharmacopeia or National Formulary monograph for it, and FDA's July 2026 review found no approved product containing it in any country it searched [1]. WADA names BPC-157 in category S0 (non-approved substances), prohibited at all times in and out of competition, and it remains named in the 2027 List [2][8].

Its compounding status has shifted. BPC-157 sat in FDA's category 2 list of bulk substances that may present significant safety risks from September 2023 until April 22, 2026, when it moved to a 'nominated but withdrawn' table because the nominating groups withdrew; removal was not a finding of safety [7][9]. It is in none of the three categories on FDA's list of nominated bulk substances, so FDA's category 1 policy does not cover it [10]. On July 23, 2026 the Pharmacy Compounding Advisory Committee voted in favor of adding it to the pharmacy bulks list, against FDA staff's recommendation; that vote is advice only and BPC-157 is not on the list [11][9].

HHS's October 2026 draft enforcement-discretion policy is not an approval and does not put BPC-157 on any list [12]. Among its conditions for the peptides it covers, serious adverse events and quality problems must be reported to FDA MedWatch, and it names state-licensed pharmacies, federal facilities and licensed physicians rather than outsourcing facilities [9][12].

The bottom line

There is no FDA-approved BPC-157 product or approved product label. Beyond the three adverse-event reports, the record consists of a handful of small human studies and animal findings [1][6].